Expert Insights: Dr. Andrew Brenner on the Path Forward
In a recent video interview with Sabrina McCrear of AJMC – The American Journal of Managed Care, Andrew Brenner, MD, PhD, provided a deeper look into the significance of the SABCS presentations.
Dr. Brenner discussed key takeaways from the conference and explained how Plus Therapeutics’ clinical progress could influence the future of leptomeningeal metastases treatment.
Watch the full interview: https://lnkd.in/gZayxFUS
Addressing an Urgent Medical Need
Leptomeningeal metastases remain one of the most difficult complications of advanced cancer, particularly among patients with metastatic breast cancer. The data shared at SABCS represent continued progress toward developing safer, more effective therapies that may improve both survival and quality of life.
Through its ongoing clinical programs, Plus Therapeutics continues to pursue solutions for patients facing limited treatment options.
#PlusTherapeutics #PSTV #SABCS2025 #ClinicalTrial #ClinicalTrials #BreastCancer #LeptomeningealMetastases #Radiotherapeutic #NeuroOncology #CancerResearch #OncologyInnovation #CancerTreatment #PrecisionMedicine
Recent Comments